• Publications
  • Influence
The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma
Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showedExpand
  • 18
  • 1
  • PDF
ROCK inhibitor reduces Myc-induced apoptosis and mediates immortalization of human keratinocytes
The Myc/Max/Mad network plays a critical role in cell proliferation, differentiation and apoptosis and c-Myc is overexpressed in many cancers, including HPV-positive cervical cancer cell lines.Expand
  • 19
  • PDF
CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition
FDA-approved kinase inhibitors are now used for melanoma, including combinations of the MEK inhibitor trametinib, and BRAF inhibitor dabrafenib for BRAFV600 mutations. NRAS-mutated cell lines areExpand
  • 5
  • PDF
Inorganic polyphosphates are important for cell survival and motility of human skin keratinocytes
CCL22 in keratinocytes may be an effective target for the treatment of inflammatory skin diseases (7, S2). These preclinical and clinical studies also suggest that TARC/CCL17 and MDC/CCL22 areExpand
  • 9
CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis
CD133, known as prominin1, is a penta-span transmembrane glycoprotein presumably a cancer stem cell marker for carcinomas, glioblastomas, and melanomas. We showed that CD133(+) ‘melanoma-initiatingExpand
  • 4
  • PDF
Abstract 3891: CD133 is associated with resistance of melanoma to multikinase inhibition
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Purpose: High-risk melanoma is a lethal cancer with a high recurrence rates and variable disease-free intervals, due toExpand
  • 1
Abstract 4224: CD133 knockdown sensitizes melanoma to kinase inhibitors
Melanoma is an aggressive and lethal form of cancer, responsible for 9,710 deaths in the US every year, as indicated by the Surveillance Epidemiology and End Results (SEER) program. Although earlyExpand
  • 1
Abstract 2501: Combination therapy with mebendazole, trametinib and metformin eliminates recalcitrant NRASQ61Kmelanoma cells
Melanoma is an aggressive and lethal form of cancer with increasing incidence worldwide. In recent years, the FDA approved several promising treatments for malignant melanoma. However, treatmentExpand
Abstract 3860: The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma
Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showedExpand